E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy
2025

E‐52862 for Chronic Pain Relief

Sample size: 279 publication 10 minutes Evidence: moderate

Author Information

Author(s): Rafael Gálvez, Victor Mayoral, Jesús Cebrecos, Francisco J. Medel, Adelaida Morte, Mariano Sust, Anna Vaqué, Antonio Montes‐Pérez, Fernando Neira‐Reina, Luz Cánovas, César Margarit, Didier Bouhassira

Primary Institution: ESTEVE Pharmaceuticals S.A.

Hypothesis

E‐52862, a selective sigma‐1 receptor antagonist, will provide effective pain relief in patients with chronic postsurgical pain and painful diabetic neuropathy.

Conclusion

E‐52862 provided superior relief of chronic postsurgical pain compared to placebo, while its effectiveness in painful diabetic neuropathy was less clear due to high placebo response rates.

Supporting Evidence

  • E‐52862 showed a significant reduction in average pain scores for chronic postsurgical pain compared to placebo.
  • In painful diabetic neuropathy, E‐52862 did not show a significant difference in pain reduction compared to placebo.
  • The studies included a total of 279 patients across both conditions.
  • E‐52862 was well tolerated with an acceptable safety profile.

Takeaway

This study tested a new medicine called E‐52862 to help people with severe pain after surgery or from diabetes. It worked better than a fake pill for surgery pain, but not as well for diabetes pain.

Methodology

Two randomized, double-blind, placebo-controlled phase 2 studies were conducted with patients receiving either E‐52862 or placebo for 4 weeks.

Potential Biases

The high frequency of treatment-emergent adverse events in the CPSP study could lead to guessing of treatment assignments.

Limitations

The studies had a short duration, a relatively small number of patients, and high placebo response rates in the PDN study.

Participant Demographics

Patients were predominantly white, with a median age of 53 years for CPSP and 61 years for PDN.

Statistical Information

P-Value

0.029

Confidence Interval

−1.7, −0.1

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/ejp.4755

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication